Literature DB >> 24937559

Alexithymia and anxiety sensitivity in Turkish depressive, anxiety and somatoform disorder outpatients *.

Feryal Cam Celikel1, Omer Saatcioglu.   

Abstract

Objective. To assess the relations between anxiety sensitivity, and dimensions of alexithymia in somatoform, anxiety and depressive disorder patients. Methods. The sample consisted of 124 patients with the diagnosis of depressive, anxiety, or somatoform spectrum disorders (DSM-IV). Toronto Alexithymia Scale (TAS-20), 16-item Anxiety Sensitivity Index (ASI), Hamilton Depression (HDRS), and Anxiety (HAS) scales were used. Results. The total sample (n=124) was divided into three diagnostic categories. There was one Depression Group (n=69). Due to small sample sizes, diagnoses in anxiety and somatoform spectrum disorders were combined in two relatively larger Anxiety (n=42) and Somatoform Groups (n=13) for statistical purposes. No statistically significant difference was found in the TAS-20 total or subscale scores between the three diagnostic groups. In all three diagnostic groups, there was a strong and significant positive correlation between ASI and TAS-20 total scores. In all three groups, there was a significant positive correlation between TAS-20 Factor 1 and ASI. In the Depression and Somatoform Groups, ASI scores were found to be significantly positively correlated with scores on TAS-20 Factor 2. Conclusion. This study reveals that alexithymia does not differentiate depressive, anxiety, or somatoform disorders, yet suggests a functional relation with anxiety sensitivity on a subscale basis.

Entities:  

Keywords:  Alexithymia; anxiety; anxiety sensitivity; depression; somatoform

Year:  2007        PMID: 24937559     DOI: 10.1080/13651500600971521

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  1 in total

1.  Panic Disorder as Unthinkable Emotions: Alexithymia in Panic Disorder, a Croatian Cross-Sectional Study.

Authors:  Daniela Šago; Goran Babić; Žarko Bajić; Igor Filipčić
Journal:  Front Psychiatry       Date:  2020-05-20       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.